400 PROFESSIONAL DR, SUITE 400, GAITHERSBURG, MD
Market cap: $676.8M (12/22/2025)
Price: $12.54
Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site
Announces Retirement of Dr. Louis W. Sullivan from Board of Directors
Reports Third Quarter 2025 Financial Results
Emergent BioSolutions Wins New U.S. Government Contract for ACAM2000® Vaccine
Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
Reports Second Quarter 2025 Financial Results
Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply
In Re Stockholder Derivative Litigation
Q3
Q2
Q1
FY 2024
FY 2023
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Amended Registration Statement for Securities
S-1
Definitive Proxy Statement
Additional Proxy Materials
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement
S-8 POS
Definitive Revised Proxy Statement
Submission Upload
Correspondence
Confidential Treatment Order